Abiopharma

🔍 Jordan Blair (Director)

Company: ETHZilla Corp (ETHZ)

Report Date: 2025-08-21

Detailed Transactions and Holdings:

• Sold 200,000 shares of Common Stock (Direct)
  Date: 2025-08-21 | Code: J | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-21 | Code: H | nature_of_ownership: Through Blair Jordan Strategy and Finance Consulting Inc. | shares_owned_after: 327,576.00 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-21 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 43,166.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-21 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 1,318,000.00 | Footnotes: F6

Footnotes:

• F1: Mr. Jordan owns and controls Blair Jordan Strategy and Finance Consulting Inc. and as such is deemed to beneficially own the securities held by such entity.
• F2: On February 5, 2025, the Issuer, the Reporting Person and Dr. James Woody, entered into a Voting Agreement, whereby Dr. Woody agreed to vote a total of 43,166 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to February 5, 2026, the date after August 5, 2025, that Dr. Woody has sold all of the shares or the date that the Issuer terminates the Voting Agreement. In order to enforce the terms of the Voting Agreement, Dr. Woody provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 43,166 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.
• F3: As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 43,166 shares of common stock of the Issuer held by Dr. Woody. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein.
• F4: On August 21, 2025, the Voting Agreement discussed in footnote (5) below expired pursuant to its terms.
• F5: On February 21, 2025, the Issuer, the Reporting Person and Dr. Marlene Krauss, entered into a Voting Agreement, whereby Dr. Krauss agreed to vote a total of 200,000 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to August 21, 2025. In order to enforce the terms of the Voting Agreement, Dr. Krauss provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 200,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.
• F6: On April 28, 2025, the Issuer, the Reporting Person and Elray Resources, Inc. ("Elray") entered into a Voting Agreement, whereby Elray agreed to vote a total of 1,318,000 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to April 28, 2026. In order to enforce the terms of the Voting Agreement, Elray provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 1,318,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.
• F7: As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 1,318,000 shares of common stock of the Issuer held by Elray. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein.